Study Design Background
Results:
The mean half-life (t ½ ) of celecoxib was similar in the presence (10.3 hr) and absence (10.8 hr) of vadadustat. Co-administration of vadadustat and celecoxib resulted in a 12% and 11% increase in celecoxib AUC 0-t and AUC 0-inf , respectively, and a 60% increase in C max . Based on the 90% confidence intervals for the geometric mean ratios for AUC 0-t and AUC 0-inf , no significant DDI was observed between vadadustat and celecoxib. Two mild AEs (flushing and headache) were reported in 2 patients.
Conclusions:
The similarity in celecoxib AUC when dosed with or without vadadustat, indicates that vadadustat has no clinically significant interaction with CYP2C9-sensitive substrates. The transient effect on celecoxib C max is not considered clinically relevant. Vadadustat may be administered with medications metabolized by CYP2C9 without the need to modify the dose of the co-administered drug. • Safety and tolerability of seven consecutive daily doses of vadadustat 600 mg
Methods
• Safety and tolerability of celecoxib administered alone and following multiple daily doses of vadadustat
Vadadustat

• Vadadustat is a small molecule inhibitor of HIF prolyl-hydroxylases (HIF-PH)
• HIF is the primary regulator of the production of red blood cells (RBCs) and acts by simulating the body's physiologic response to hypoxia
• By inhibiting HIF-PH enzymes, vadadustat stabilizes HIF proteins resulting in an increase in erythropoietin (EPO) secretion, RBC production, and iron delivery to the bone marrow
Clinical Development of Vadadustat
• Being developed for the treatment of anemia secondary to chronic kidney disease (CKD)
• To date, it has been evaluated in 15 completed Phase 1 and Phase 2 studies and is well-tolerated in both healthy volunteers and CKD patients
• Administered as once-daily oral tablets and dose adjusted based on a patient's hemoglobin response
• Induces diurnal variation in EPO concentrations while maintaining physiologic range
• Facilitates iron homeostasis by decreasing levels of hepcidin and ferritin, as well as increasing total iron binding capacity
Pharmacokinetics of Vadadustat
• Vadadustat is an orally bioavailable molecule with a half-life of approximately 4 hours in healthy volunteers allowing once-a-day dosing
• Vadadustat is metabolized to pharmacologically inactive O-and acyl-glucuronides and undergoes dual clearance via urinary excretion and fecal elimination
• In vitro data suggests that vadadustat does not inhibit CYP3A4 and, therefore, interactions with drugs such as atorvastatin are highly unlikely
• Based on in vitro data, vadadustat is a weak inhibitor of CYP2C9
• Here we present the results from a study in healthy volunteers receiving vadadustat and the CYP2C9 substrate celecoxib • Vadadustat may be administered with medications metabolized by CYP2C9 without the need to modify the dose of the co-administered drug
• The increase in C max of celecoxib administered with vadadustat versus alone appeared to be transient since the impact on the overall extent of absorption (AUC) was minimal, and other PK parameters (t ½ and CL/F) were unaffected
• Vadadustat was well-tolerated when administered concomitantly with celecoxib
The authors thank Karishma Manzur, PhD (Akebia Therapeutics, Inc.) for medical writing support, and Lucid Partners Ltd. for editorial support. • Two adverse events of mild headache and mild flushing were reported in 2 patients
• Both events resolved without requiring treatment and did not recur with continued dosing of vadadustat 
Summary of Adverse Events
